New drug combo shows promise against advanced skin cancer
NCT ID NCT04889118
First seen Dec 31, 2025 · Last updated May 20, 2026 · Updated 28 times
Summary
This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that cannot be removed by surgery. It involved 131 Chinese patients who had not received prior treatment for their advanced disease. The goal was to see if the combination slows cancer growth or improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital (0601)
Beijing, Beijing Municipality, 100036, China
-
Fudan University Shanghai Cancer Center ( Site 0607)
Shanghai, Shanghai Municipality, 200032, China
-
Fujian Provincial Cancer Hospital ( Site 0612)
Fuzhou, Fujian, 350014, China
-
Henan Cancer Hospital ( Site 0610)
Zhengzhou, Henan, 450003, China
-
Nanjing Drum Tower Hospital (0609)
Nanjing, Jiangsu, 210008, China
-
Sir Run Run Shaw Hospital (0605)
Hangzhou, Zhejiang, 310018, China
-
Sun Yat-Sen University Cancer Center (0602)
Guangzhou, Guangdong, 510000, China
-
The First Hospital Of Jilin University (0603)
Changchun, Jilin, 130021, China
-
Tianjin Medical University Cancer Institute & Hospital (0606)
Tianjin, Tianjin Municipality, 300060, China
-
Yunnan Cancer Hospital (0604)
Kunming, Yunnan, 430030, China
-
Zhejiang Cancer Hospital ( Site 0608)
Hangzhou, Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.